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Bone morphogenetic proteins (BMPs) are ﬁrmly implicated as intra-
ovarian regulators of follicle development and steroidogenesis. Here
we report a microarray analysis showing that treatment of cultured
bovine theca cells (TC) with BMP6 signiﬁcantly (>twofold; P < 0.01)
up- or down-regulated expression of 445 genes. Insulin-like peptide
3 (INSL3) was the most heavily down-regulated gene (−43-fold) with
cytochrome P450, subfamily XVII (CYP17A1) and other key steroido-
genic transcripts including steroidogenic acute regulatory protein
(STAR), cytochrome P450 family 11, subfamily A1 (CYP11A1) and
3 beta-hydroxysteroid dehydrogenase type 1 (HSD3B1) also down-
regulated. BMP6 also reduced expression of nuclear receptor sub-
family 5A1 (NR5A1) known to target the promoter regions of the
aforementioned genes. Real-time PCR conﬁrmed these ﬁndings and
also revealed a marked reduction in expression of INSL3 receptor,
relaxin/insulin-like family peptide receptor 2 (RXFP2). Secretion of
INSL3 protein and androstenedione were also suppressed suggest-
ing a functional link between BMP and INSL3 pathways in control-
ling androgen synthesis. RNAi-mediated knockdown of INSL3
reduced INSL3 mRNA (75%) and protein (94%) level and elicited
a 77% reduction in CYP17A1 mRNA and 83% reduction in andro-
stenedione secretion. Knockdown of RXFP2 also reduced CYP17A1
expression (81%) and androstenedione secretion (88%). Conversely,
treatment with exogenous (human) INSL3 increased androstene-
dione secretion ∼twofold. The CYP17A1 inhibitor abiraterone abol-
ished androgen secretion and reduced expression of both INSL3 and
RXFP2. Collectively, these ﬁndings indicate a positive autoregulatory
role for INSL3 signaling in maintaining thecal androgen production,
and visa versa. Moreover, BMP6-induced suppression of thecal an-
drogen synthesis may be mediated, at least in part, by reduced
INSL3-RXFP2 signaling.
growth factor | ovary | reproduction
Ovarian androgen synthesis is obligatory for normal ovarianfollicle development, estrogen production, ovulation, and
female fertility in animals and humans. However, ovarian
hyperandrogenism, a feature of the widespread polycystic ovar-
ian syndrome (PCOS) in women, is detrimental to fertility and
has other adverse consequences for the affected individual (e.g.,
hirsutism, acne, and metabolic manifestations) (1, 2). Although
pituitary luteinizing hormone (LH) has long been recognized as
a primary driver of androgen synthesis by theca interna cells of
the mammalian ovarian follicle (3, 4), evidence has emerged
implicating a variety of intraovarian factors as having modulatory
roles in this process, including inhibins, activins, and bone mor-
phogenetic proteins (BMPs) (reviewed in refs 5–8). Additional
proteins, including insulin-like growth factors (IGFs), EGF,
TGF-α, and TNF-α, have also been shown to modulate thecal
androgen production in different in vitro model systems (9–12).
Previous studies using a primary bovine ovarian theca interna
cell culture model showed that different BMPs (BMP2, BMP4,
BMP6, and BMP7) potently suppress basal and LH-induced an-
drogen secretion (13) and that their action can be antagonized by
inhibin (14). Because multiple BMPs, along with their signaling
receptors, antagonists (e.g., inhibin), and extracellular binding
proteins (e.g., gremlin, chordin, and noggin) are widely expressed
in different intraovarian compartments, including theca (TCs),
granulosa cells (GCs), and ovarian stroma (14–18), it is likely that
BMPs exert autocrine/paracrine actions to regulate follicular ste-
roidogenesis, as well as other aspects of ovarian function (5, 8).
Our previous ﬁndings led us to hypothesize that a functional
deﬁcit in thecal BMP signaling could be a contributory factor in
the etiology of hyperandrogenemic disorders such as PCOS (13).
Conversely, a functional excess of thecal BMP signaling could
contribute to androgen insufﬁciency. Both situations compromise
normal follicle development, leading to subfertility or infertility in
animals and humans, as well as other extraovarian consequences
arising from the perturbation of sex hormone output.
To gain further insight into the mechanism through which
BMP suppresses ovarian androgen production, we undertook
a microarray analysis of global gene expression in bovine TCs
exposed to BMP6 under both basal and LH-stimulated con-
ditions. As documented here, this experiment led to the un-
expected identiﬁcation of insulin-like factor 3 (INSL3) as the
most heavily down-regulated transcript in BMP-treated cells.
INSL3 has a well-documented role in the development of the
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male reproductive system, being involved in the ﬁrst (trans-
abdominal) phase of testicular descent (19). Although it has
been known for some time that INSL3 is also expressed in the
adult ovary, primarily in TCs (20) and luteal tissue (21, 22), its
potential physiological role in the regulation of ovarian func-
tion and steroidogenesis is poorly deﬁned. On the basis of our
microarray ﬁndings presented here, we therefore designed and
executed a further series of experiments to (i) conﬁrm that
BMP treatment suppresses INSL3 secretion; (ii) establish the
dose- and time-dependency of the response to BMP6; (iii) ex-
plore the possibility that INSL3 signaling is a requirement for
thecal androgen production; (iv) investigate whether INSL3
signaling actually mediates the suppressive effect of BMP on
thecal androgen production or, alternatively; (v) whether BMP
comodulates expression of INSL3 along with one or more key
components of the steroidogenic pathway.
Results
Microarray Analysis: Global Effect of BMP6 Treatment on TC Gene
Expression. The 24,128 probesets on the array represented
19,023 unique transcripts, of which 15,464 remained on the list
ﬁltered to exclude those with low (unreliable) hybridization sig-
nal intensity. After ﬁltering the data to enrich transcripts dis-
playing a signiﬁcant difference (corrected P < 0.01) in at least
one of four condition pairs, 2,550 transcripts remained. After
ﬁltering this list to only retain transcripts satisfying a fold change
cutoff ≥2 [corrected P < 0.01; ANOVA with post hoc Tukey’s
honestly signiﬁcant difference (HSD) test] in at least one of the
four condition pairs, there were 498 transcripts. Clustering anal-
ysis generated a hierarchical condition tree and heatmap repre-
senting this set of transcripts (Fig. 1). This shows a strong effect
of BMP6 treatment on the gene expression proﬁle, with a much
weaker effect of LH. None of these differences in response to LH
treatment was found to be statistically signiﬁcant after applying
Benjamini-Hochberg correction, despite the fact that, on a priori
grounds, several of these genes, including steroidogenic acute
regulatory protein (STAR) (2.8-fold up-regulation) and cyto-
chrome P450, subfamily XVII (CYP17A1) (2.5-fold up-regulation)
were expected to respond to LH treatment, being well-established
targets of LH.
Given these results and to simplify further analysis focusing on
the effect of BMP6, a decision was reached to combine basal and
LH treatment groups to give two groups (n= 8 each), comparing
cells cultured in the presence or absence of BMP6. This gener-
ated a ﬁltered list of 445 unique transcripts that were signiﬁcantly
down- or up-regulated (>twofold; corrected P < 0.01) in response
to BMP6 treatment. Tables 1 and 2 show the top 20 transcripts
from these lists that were down- or up-regulated. The full gene
lists may be found in Tables S1 and S2. Notable at the top of the
list of genes down-regulated by BMP6 was INSL3 (43-fold), with
inhibin α (INHA; 14-fold; third place), CYP17A1 (11-fold; sixth
place), STAR (5.5-fold; 17th place), and CYP11A1 (5.3-fold; 19th
place) also heavily suppressed. Genes prominently up-regulated
by BMP6 included uroplakin 1B (UPK1B; 7.2-fold), sterile αmotif
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Fig. 1. Hierarchical cluster analysis and heatmap representing 498 differ-
entially expressed genes (>twofold up- or down-regulation, P < 0.01 in at
least one condition pair) among the four treatment groups (C, control; L, LH;
B, BMP6; L+B, LH + BMP6; n = 4 arrays per treatment). Note the major effect
of BMP treatment in comparison with the much more limited effect of LH
treatment.
Table 1. Rank order list showing top 20 of 202 transcripts identiﬁed by microarray analysis as being signiﬁcantly (P < 0.01)
down-regulated >twofold in bovine TCs in response to BMP6 treatment
Order Affymetrix_ID Entrez ID Gene symbol Gene title Fold change
1 Bt.12186.1.S1_at 281870 INSL3 Insulin-like 3 (Leydig cell) −43.47
2 Bt.11438.1.S1_at 511094 TNNI3 Troponin I type 3 (cardiac) −15.24
3 Bt.4897.1.S1_at 281254 INHA Inhibin, alpha −14.44
4 Bt.16678.1.S1_at 767968 BEX2 Brain expressed X-linked 2 −12.21
5 Bt.1922.1.S1_at NA NA NA −11.90
6 Bt.3985.1.S1_at 281739 CYP17A1 Cytochrome P450, family 17, subfamily A1 −11.07
7 Bt.10630.1.S1_at 506584 NMB Neuromedin B −10.72
8 Bt.643.1.S1_at NA NA NA −10.57
9 Bt.13796.1.S1_at 783399 LOC783399 Major allergen Equ c 1-like −9.59
10 Bt.12916.1.S1_at 281210 GPX3 Glutathione peroxidase 3 (plasma) −7.73
11 Bt.23393.1.S1_at 515161 ATP1A2 ATPase, Na+/K+ transporting, alpha 2 polypeptide −7.37
12 Bt.10150.1.S1_at NA NA NA −7.24
13 Bt.25052.1.S1_at 539360 CAPN6 Calpain 6 −7.05
14 Bt.21896.1.S1_at NA NA NA −6.22
15 Bt.12405.1.S1_at 538276 LOC538276 Similar to Janus kinase 3 −6.11
16 Bt.4760.1.S1_at 281824 HSD3B1 Hydroxy-steroid dehydrogenase, type 3 beta −5.77
17 Bt.4709.1.S1_at 281507 STAR Steroidogenic acute regulatory protein −5.54
18 Bt.2122.1.S1_at 282604 FDXR Ferredoxin reductase −5.34
19 Bt.7190.1.S1_at 338048 CYP11A1 Cytochrome P450, family 11, subfamily A1 −5.28
20 Bt.25738.1.A1_at 505855 ERP27 Endoplasmic reticulum protein 27 −5.23
NA, not applicable.
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domain containing 11 (SAMD11; 6.6-fold), and inhibitor of dif-
ferentiation/DNA binding 1 (ID1; 6.5-fold), the latter being
a well-established BMP-responsive target gene.
The list of 445 genes signiﬁcantly (P < 0.01) down- or up-
regulated >twofold in response to BMP6 treatment was sub-
jected to Gene Ontology (GO) enrichment analysis. A total of 89
GO classiﬁcation terms were signiﬁcantly (P < 0.05) overrepre-
sented among these 445 transcripts: 12 terms in the Cellular
Component category, 54 terms in the Biological Process cate-
gory, and 23 terms in the Molecular Function category. This list
showing the percentage of the 445 transcripts signiﬁcantly over-
represented under each GO term is presented in Table S3.
RT–Quantitative PCR Validation of Microarray Data. To verify the
microarray ﬁndings we carried out RT–quantitative PCR (RT-
qPCR) analysis of a selection of transcripts, including INSL3,
STAR, CYP11A1, 3 beta-hydroxysteroid dehydrogenase type 1
(HSD3B1),CYP17A1, 17-beta-hydroxysteroid dehydrogenase type 1
(HSD17B1), luteinizing hormone/choriogonadotropin receptor
(LHCGR), inhibin alpha (INHA), nuclear receptor subfamily 5A1
(NR5A1), and ID1. Genes found to be signiﬁcantly up- or down-
regulated by BMP6 by microarray were correspondingly shown to
be up- or down-regulated by RT-qPCR (Fig. 2). In addition, the
cognate receptor for INSL3, relaxin/insulin-like family peptide
receptor 2 (RXFP2), which was not represented on the microarray,
was found by RT-qPCR to be heavily down-regulated by BMP6
under both basal and LH-stimulated conditions.
Effect of BMP6 on Secretion of INSL3 Protein. Fig. 3 provides con-
ﬁrmation that the inhibitory action of BMP6 on expression of
INSL3 mRNA detected by microarray analysis and RT-qPCR is
accompanied by a corresponding reduction in secretion of INSL3
protein by the cells.
Do Other BMPs Suppress Expression of INSL3 and RXFP2? Fig. 4
shows a comparison of the effects of BMP2, -4, -6, and -7 on
androstenedione (A4) and INSL3 secretion and expression of
mRNA for INSL3 and its receptor RXFP2. At the dose level
tested (10 ng/mL) all four BMPs had comparable inhibitory
effects on each of the above endpoints.
Time Course of BMP6 Action on Expression of INSL3, RXFP2, and Other
Transcripts. To examine the time course of the response to BMP6,
cells were lysed at a ﬁxed time on day 6 of culture, having been
exposed to BMP6 (10 ng/mL) for the preceding 0-, 4-, 24-, 48-, or
96-h periods. As shown in Fig. 5A expression of ID1, a classic
BMP-responsive gene, increased markedly in response to BMP6,
with a signiﬁcant increase (∼fourfold; P < 0.05) detected as early as
4 h after starting treatment. At the same time point expression of
RXFP2 was signiﬁcantly reduced (38%, P < 0.05). Expression of
INSL3, CYP17A1, STAR, CYP11A1, HSD3B1, LHCGR, NR5A1,
and nuclear receptor subfamily 0, group B, member 1 (NROB1)
was down-regulated by BMP6, with each transcript following
a broadly similar time course but with none showing a signiﬁcant
decline at 4 h after treatment. In each case the maximal decline was
observed after the full 96-h period of BMP6 treatment. Fig. 5B
shows the corresponding time course for A4 and INSL3 secretion.
Does Knockdown of Endogenous INSL3 or RXFP2 Affect CYP17A1
Expression and Androgen Secretion? As shown in Fig. 6A, trans-
fection of TCs with an siRNA duplex targeted at INSL3 reduced
INSL3 mRNA level by 75% (P < 0.01) and secreted INSL3
protein level by ∼94% (P < 0.01) relative to values in cells ex-
posed to nonsilencing control duplex. This was accompanied by
a 77% reduction in CYP17A1 mRNA level (P < 0.01) and 83%
reduction in A4 secretion (P < 0.05). Fig. 6B shows that trans-
fection with an siRNA duplex targeted at RXFP2 reduced
RXFP2 mRNA level by 80% (P < 0.01) and that this also led to
a marked reduction in CYP17A1 mRNA level (81%; P < 0.01)
and A4 secretion (88%; P < 0.01).
Does Synthetic Human INSL3 Modulate Androgen Secretion by Bovine
TCs? As shown in Fig. 7 treatment of bovine TCs with LH elicited
the anticipated biphasic response in terms of A4 secretion (P <
0.001), with a maximal response observed at 150 pg/mL Treatment
with synthetic human INSL3 promoted a modest (∼twofold) in-
crease in A4 secretion under basal and LH-stimulated conditions
(P < 0.05), although the effect was not dose dependent, being
evident at the lowest dose level tested (0.5 ng/mL). There was no
LH × INSL3 treatment interaction (P = 0.9, two-way ANOVA).
Table 2. Rank order list showing top 20 of 243 transcripts identiﬁed by microarray analysis as being signiﬁcantly (P < 0.01)
up-regulated >twofold in bovine TCs in response to BMP6 treatment
Order Affymetrix ID Entrez ID Gene symbol Gene title Fold change
1 Bt.4089.1.S1_at 282113 UPK1B Uroplakin 1B 7.23
2 Bt.19485.1.A1_at 100140500 SAMD11 Sterile α motif domain containing 11 6.63
3 Bt.1730.1.A1_at 497011 ID1 Inhibitor of DNA binding 1 6.51
4 Bt.29871.1.S1_at 282497 BOLA-DYA MHC, class II, DY alpha 6.51
5 Bt.25769.1.A1_at 539199 LOC539199 Similar to MAM domain containing 2 6.22
6 Bt.22389.1.S1_at 617336 SHISA2 Shisa homolog 2 (Xenopus laevis) 5.58
7 Bt.19909.1.A1_at NA NA 5.38
8 Bt.24625.1.S1_at 618793 FOXO4 Forkhead box O4 5.34
9 Bt.5007.1.A1_at 508098 LOC508098 Hypothetical LOC508098 5.33
10 Bt.23126.1.S1_at 282876 NOS2 Nitric oxide synthase 2, inducible 5.25
11 Bt.20501.1.S1_at NA NA 4.77
12 Bt.18639.1.A1_at 513776 FBXO32 F-box protein 32 4.62
13 Bt.26774.1.S1_at 537487 IGSF10 Ig superfamily, member 10 4.60
14 Bt.24212.1.S1_at 534650 RSPO3 R-spondin 3 homolog (Xenopus laevis) 4.55
15 Bt.22746.1.S1_at 505366 WFDC1 WAP four-disulﬁde core domain 1 4.34
16 Bt.20148.1.S1_at NA NA 4.30
17 Bt.13363.1.A1_at NA NA 4.23
18 Bt.15758.1.S1_at 282023 PTGS2 Prostaglandin-endoperoxide synthase 2 4.22
19 Bt.262.1.S1_at 404105 TKDP3 Trophoblast Kunitz domain protein 3 4.20
20 Bt.3546.1.S1_at 785924 ROR2 Receptor tyrosine kinase-like orphan receptor 2 4.14
NA, not applicable.
E1428 | www.pnas.org/cgi/doi/10.1073/pnas.1222216110 Glister et al.
Does Direct Inhibition of Androgen Synthesis Affect Expression of
INSL3 or RXFP2? Exposure of TCs to abiraterone abolished A4
secretion (P < 0.001), conﬁrming its action as a potent inhibitor
of CYP17A1 (Fig. 8). Expression of mRNA for INSL3 and its
receptor RXFP2 were both reduced by ∼50% (P < 0.05) in
abiraterone-treated cells. Mean INSL3 protein secretion level
was also ∼50% lower in abiraterone-treated cells, but the dif-
ference was not statistically signiﬁcant.
What Other Intraovarian Factors Affect TC Expression of INSL3? As
shown in Fig. 9 treatment of TCs with LH alone promoted
a robust (eightfold; P < 0.05) increase in A4 secretion but did not
affect INSL3 mRNA level or INSL3 protein secretion. Treat-
ment with EGF, TGF-α, or TNF-α promoted marked reductions
(P < 0.05) in A4 secretion, INSL3 mRNA level, and INSL3
protein secretion under both basal and LH-stimulated con-
ditions. In addition, cotreatment of cells with inhibin-A reversed
the suppressive effects of BMP4, -6, and -7 on INSL3 mRNA
level and INSL3 protein secretion (Fig. 10).
Ingenuity Pathway Analysis Suggesting Functional Associations
Between TC Genes Up- or Down-Regulated by BMP6 Treatment.
The list of 445 genes shown to be up-or down-regulated by
BMP6 (>twofold; P < 0.01) in the microarray study was exported
to Ingenuity Pathway Analysis (IPA) software for pathway
analysis. This generated a network that linked 88 of the 445
genes on the basis of previously reported functional inter-
actions (Fig. 11). Multiple nodes were evident in the gene
network, but it is notable that NR5A1 (steroidogenic factor 1,
SF-1) formed one prominent node radiating direct links to
INSL3, INHA, CYP17A1, CYP11A1, STAR, LHCGR, scavenger
receptor class B, member 1 (SCARB1), and NR0B1. Expression
of each of these genes was signiﬁcantly down-regulated by
BMP6 treatment.
Discussion
According to the “two cell-two gonadotropin” model of ovarian
estrogen synthesis (23–25) pituitary LH acts on TCs to promote
the synthesis of androgens that diffuse to neighboring GCs to act
as substrate for cytochrome P450, family 19, subfamily A, poly-
peptide 1 (CYP19A1) (CYP19A1), whose expression is induced
by pituitary follicle stimulating hormone. CYP19A1 then con-
verts androgens into estrone and estradiol-17β. Because GCs do
not express CYP17A1 they are unable to synthesize androgens de
novo, and thus TC–GC cooperation is essential for the follicular
unit to fulﬁll its all-important role of secreting estrogens, which
are vital for multiple aspects of female reproduction and other
physiological processes. Although this basic model remains valid,
there are many aspects of the mutual interplay between GCs and
TCs that have yet to be resolved, and it is increasingly evident
that local autocrine/paracrine signaling must play a prominent
role and that GCs, in turn, modulate TC function (25). Com-
pelling evidence, largely from in vitro studies in rodents, indi-
cates that locally produced growth factors, including various
members of the TGF-β superfamily, are expressed by GCs, TCs,
and oocytes in a developmental stage-related manner and
contribute to the regulation of follicle development and ste-
roidogenesis (reviews in refs. 5, 6, 8, and 26). Notable among
these are BMPs, activins, and inhibins. As discussed here, an-
other peptide unrelated to the TGF-β family, INSL3, is known
to be expressed abundantly in ovarian TC and, to a lesser ex-
tent, corpus luteum (20, 22, 27, 28), but its functional role in the
ovary has remained obscure.
The ﬁnding from our microarray study that treatment of bovine
TCs with BMP6 promotes a profound reduction in expression of
INSL3 concomitantly with reduced androgen secretion and di-
minished expression of CYP17A1 and other transcripts involved
in steroidogenesis suggests a functional link between INSL3
signaling and thecal steroidogenesis and prompted further
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Fig. 2. RT-qPCR conﬁrmation of microarray ﬁndings for selected transcripts
shown to be affected by BMP6 treatment. Note that RXFP2 was not repre-
sented on the microarray. Values are means, and vertical bars indicate SEM
(n = 4 independent cultures). Means without a common letter are signiﬁ-
cantly different (P < 0.05).
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investigation. Having conﬁrmed that the BMP6-induced reduc-
tion in INSL3 mRNA expression was accompanied by a corre-
sponding inhibition of INSL3 protein secretion by the cells, we
showed that three other BMPs (BMP2, BMP4, and BMP7) known
to be expressed in bovine follicles (14, 17, 29) exerted a similar
suppressive action on INSL3 expression, at both the mRNA and
protein level. Moreover, BMP treatment suppressed thecal ex-
pression of RXFP2, the cognate signaling receptor for INSL3 (30)
that is coexpressed with INSL3 in follicular theca cells (28, 31).
On the basis of these ﬁndings, we hypothesized that the BMP-
induced suppression of thecal androgen production might actually
be mediated via an inhibition of thecal INSL3-RXFP2 signaling
acting in an autocrine/paracrine manner. To address this we ﬁrst
examined the time course of the response to BMP treatment
with the prediction that a BMP-induced decline in INSL3 and/
or RXFP2 expression would precede the corresponding fall in
expression of CYP17A1 and other steroidogenesis-related
transcripts. If so, this would support our hypothesis. In the
event, a signiﬁcant BMP-induced down-regulation of INSL3
mRNA was ﬁrst detected after 24 h of treatment, coincident
with a signiﬁcant decline in CYP17A1, CYP11A1, HSD3B1, and
LHCGR expression, as well as A4 secretion. Although the mean
INSL3 protein secretion level was ∼40% lower at 24 h, this de-
cline was not statistically signiﬁcant. However, a signiﬁcant fall in
RXFP2 expression was detected just 4 h after BMP treatment,
coincident with a signiﬁcant up-regulation of the classic BMP-
responsive gene ID1 (32, 33). As such, this observation provides
partial support for the above hypothesis.
Next we used an RNA interference approach to investigate the
dependency of TC androgen production on INSL3-RXFP2 sig-
naling. Transfection of cells with INSL3-targetted siRNA suc-
cessfully knocked down levels of INSL3 mRNA by ∼75% and
secreted protein by >90%. This was accompanied by a substantial
decline in CYP17A1 expression and A4 secretion, supporting an
obligatory role for INSL3 in maintaining TC androgen output.
Likewise, RXFP2-targeted siRNA reduced RXFP2 mRNA level
by 80%, and this was also accompanied by a marked fall in
CYP17A1 expression and A4 secretion, reinforcing this concept.
Interestingly, female mice with null mutations in insl3 reportedly
show reduced fertility associated with increased follicle atresia,
accelerated luteolysis, and extended estrous cycles (34, 35).
However, whether ovarian androgen production is affected in
insl3 null mice has not been reported.
To complement the ﬁndings of our INSL3/RXFP2 knockdown
experiments we treated TCs under basal and LH-stimulated
conditions with various concentrations of exogenous INSL3
(synthetic human), the prediction being that this would boost
androgen secretion. A small (<twofold) although statistically
signiﬁcant effect of INSL3 was seen, but there was no LH ×
INSL3 treatment interaction (P = 0.9), reinforcing the view that
autocrine/paracrine INSL3-RXFP2 signaling has a positive in-
ﬂuence on TC androgen production under both basal and LH-
stimulated conditions. The relatively modest effect of exogenous
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INSL3 on androgen secretion most likely reﬂects the high level
of endogenous INSL3 generating concentrations, particularly
near the cell membrane, sufﬁcient to promote near-maximal
INSL3 receptor (RXFP2) occupancy. In addition, because the
amino acid sequences of bovine and human INSL3 are only
about 75% homologous (22), human INSL3 may be a poor ag-
onist at the bovine receptor.
Given the above evidence that autocrine/paracrine INSL3-
RXFP2 signaling has a positive role in promoting TC androgen
production, we considered the possibility that, in a reciprocal
fashion, androgen might promote INSL3-RXFP2 signaling.
Because high levels of endogenous androgens are already present
in these cultures, rather than treating cells with exogenous andro-
gen, we used a pharmacological approach to inhibit endogenous
androgen production. Abiraterone, a potent inhibitor of CYP17A1
enzyme (36), abolished A4 secretion and reduced expression of
INSL3 and RXFP2 mRNA by ∼50%, supporting the notion of
a mutual, positive autoregulatory loop linking thecal INSL3-RXFP2
signaling and androgen synthesis. Our evidence that ovarian (the-
cal) expression of RXFP2 is positively regulated by androgens
concurs with the recent observation in male mice that testosterone
administration to androgen-deﬁcient LHCGR-null mutants up-
regulated RXFP2 expression in the gubernaculum (37).
TC expression of INSL3 is acutely up-regulated by LH/CG
treatment in rats (38), whereas longer-term treatment of bovine
TCs with a high dose level of LH or with serum (to promote
luteinization) down-regulates INSL3 expression (28, 39, 40). In
this study, involving nonluteinized TCs, no consistent stimulatory
effect of LH on INSL3 mRNA expression or secretion of INSL3
protein was seen, despite a clear-cut stimulation of A4 secretion.
This concurs with a recent human study showing that a gonado-
tropin-releasing hormone agonist-induced LH rise promotes
androgen secretion but does not raise circulating INSL levels in
either control or PCOS subjects (41). Treatment of bovine TCs
with EGF, TGF-α, and TNF-α, growth factors previously shown
to suppress thecal androgen production (10, 42, 43), uniformly
suppressed INSL3 mRNA level and INSL3 protein secretion,
reinforcing the positive association between androgen and INSL3
production by the cells. Moreover, inhibin-A cotreatment could
reverse the BMP-induced inhibition of INSL3 expression, rein-
forcing previous evidence that granulosa-derived inhibin con-
tributes to the physiological regulation of BMP signaling and, in
turn, thecal androgen synthesis (14). Although not examined in
the present study, it should also be mentioned that insulin and
IGF1 have also been shown in several species to promote thecal
androgen production in vitro (9, 12).
Earlier immunolocalization studies of bovine follicles found
that not all healthy follicles were immunopositive for INSL3
(20). Nearly half of the follicles over 10 mm in diameter lacked
immunoreactvity. However, recent RT-qPCR data (28) indicate
a progressive increase in thecal expression of mRNA for both
INSL3 and its receptor RXFP2 with antral follicle growth from
1 to 2 mm to 9 to 10 mm in diameter. The more limited sensitivity
of immunohistochemistry compared with RT-qPCR for detecting
INSL3 expression is one possible explanation for this apparent
discrepancy. Satchell et al. (28) also reported that plasma INSL3
levels peak during the preovulatory phase of the bovine estrous
cycle and then fall concomitantly with estrogen after the LH surge
as follicle luteinization occurs. This agrees with the ﬁnding of
a striking inverse relationship between the presence of INSL3 in
the theca and 3 beta-hydroxysteroid dehydrogenase type 1 protein
in the membrana granulosa (20), because 3βHSD is up-regulated
during follicle luteinization. In mouse ovary, INSL3 expression is
higher in the follicular phase than in the luteal phase, further
suggesting a positive correlation of INSL3 with follicular matu-
ration (44). Regarding other possible intraovarian roles of INSL3,
A
B
Fig. 6. siRNA-mediated knockdown of (A) INSL3 and (B) RXFP2 suppresses CYP17A1 expression and A4 secretion by bovine TCs in vitro. Relative transcript
abundance is expressed as a proportion of the average value in control cells transfected with nonsilencing control siRNA. Values are means ± SEM (n = 4
independent cultures). **P < 0.01 vs. control.
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intrabursal injection of INSL3 promoted oocyte maturation in
pregnant mare serum gonadotropin-primed rats but, unlike LH or
chorionic gonadotropin, did not induce ovulation (38). In the
bovine ovary, expression of RXFP2 mRNA is most abundant in
TCs, consistent with an autocrine/paracrine action of TC-derived
INSL3 on the same cell type (28, 45). RXFP2 is also expressed to
a lesser degree in GC and corpus luteum tissue. Serum INSL3
levels are higher in women with PCOS compared with controls
(41, 46), being positively correlated with testosterone and LH in
both groups. Moreover, in the PCOS group, INSL3 levels were
positively correlated with ovarian follicle number and “hyper-
androgenemia index” (46).
Taken together with the bovine microarray ﬁnding reported
here that BMP6 concomitantly reduces TC INSL3 expression
and androgen production, the above reports highlight the po-
tential importance of INSL3 and BMPs in the etiology of LH-
dependent ovarian hyperandrogenism and indicate the need for
further research to elucidate the contribution of INSL3-RXFP2
signaling and BMP signaling to ovarian physiology, particularly
in the context of PCOS. Despite extensive research over many
decades the etiology of this widespread although complex and
heterogeneous syndrome remains poorly understood (reviewed
in refs. 1, 2, 47, and 48). Both genetic and environmental factors
are implicated, and there is an association with insulin resistance
and hyperinsulinemia, giving rise to the experimentally sup-
ported concept that heightened exposure of theca cells to insulin
ampliﬁes LH-dependent androgen production by theca cells (47,
48). It has also been proposed that excessive exposure to andro-
gens in utero and/or adolescence could be a contributory factor in
triggering insulin resistance in later life, or that androgen excess in
utero exposure induces a persistent abnormality of follicle de-
velopment (49). Such an alteration could involve, or lead to,
perturbation of one or more intraovarian signaling systems known
to positively (e.g., INSL3, inhibin, IGF?) or negatively (e.g., BMP,
activin, TGF-α?) regulate androgen biosynthesis.
In conclusion, this study has established the importance of
INSL3-RXFP2 signaling for maintaining androgen production
by ovarian theca cells. The potent suppressive action of BMP on
thecal androgen production seems to be linked to its suppressive
action on INSL3-RXFP2 signaling and may be mediated via
down-regulation of the nuclear transcription factor NR5A1 (SF-1),
which is known to interact with the promoter/enhancer regions
of the INSL3 gene and multiple genes involved in the steroidogenic
response, including STAR, CYP11A1, CYP17A1, and LHCGR.
We suggest that a functional deﬁcit in intraovarian BMP sig-
naling could lead to ovarian androgen excess by promoting in-
creased INSL3-RXFP2 signaling and up-regulation of the above
steroidogenic genes. Further research is warranted to evaluate
this possibility, particularly in the context of PCOS.
Materials and Methods
Bovine Ovaries and Primary Culture of TCs. Theca interna cells were isolated
from adult bovine ovaries obtained from the slaughterhouse, as described
previously (13, 17). TCs pooled from ∼50 individual 4- to 6-mm follicles were
plated out in either 96-well plates (7.5 × 104 viable cells per 0.2 mL per well) for
evaluation of hormone secretion (immunoassay) and viable cell number (neu-
tral red uptake assay), or in 24-well plates (0.5 × 106 viable cells per mL per well)
for analysis of gene expression (RT-qPCR or microarray analysis). Cells were
routinely cultured for 6 d under deﬁned serum-free conditions, with treatments
present on days 3–6 inclusive. For RNA interference experiments cells were
cultured for 7 d in total. The culture medium used routinely was McCoy’s 5A
modiﬁed medium supplemented with 1% (vol/vol) antibiotic-antimycotic solu-
tion, 10 ng/mL bovine insulin, 2 mM L-glutamine, 10 mM Hepes, 5 μg/mL apo-
transferrin, 5 ng/mL sodium selenite, and 0.1% (wt/vol) BSA (all purchased from
Sigma). Antibiotic-antimycotic was omitted from the culture medium used
during transfection of cells with RNAi in accordance with the protocol provided
by the supplier (Dharmacon). Media were replenished on days 3 and 5 with
fresh media containing treatments as appropriate. Conditioned media were
retained for hormone assay, and at the end of culture cell lysates were pre-
pared using the lysis buffer component of the RNA isolation kit. Pooled lysates
from replicate wells were stored at −80°C until total RNA isolation.
Treatments. Highly puriﬁed ovine LH (oLH-S-16) was obtained from the Na-
tional Hormone and Pituitary Program. Recombinant human (rh) BMP2,
BMP4, BMP6, and BMP7 were purchased from R&D Systems. Human INSL3
was prepared by optimized solid-phase synthesis of the separate A- and
B-chains (26 and 31 residues, respectively), followed by sequential formation
of each of the three disulﬁde bonds via regioselective chemical formation
(50). The peptide was comprehensively chemically characterized by analyti-
cal RP-HPLC and MALDI-TOF MS to conﬁrm its high purity. Treatments stock
solutions were sterilized using 0.2-μm membrane ﬁlters before dilution in
sterile culture medium. The CYP17A1 inhibitor abiraterone was purchased
from Selleck Chemicals and stock solution (50 mM) prepared in DMSO. For
experiments involving knockdown of endogenous INSL3 and RXFP2, siRNAi
duplexes against bovine INSL3 (sense strand: GGCAAGACCUGCUGACCCUUU;
antisense strand: AGGGUCAGCAGGUCUUGCCUU) and bovine RXFP2 (sense
strand: CCUGAAGUGUCUACAGAAAUU; antisense strand: UUUCUGUAGA-
CACUUCAGGUU) were custom-designed and synthesized by Dharmacon
Thermo Scientiﬁc. Controls included cells transfected with a nonsilencing
control RNAi (NSC3; Dharmacon), as well as cells exposed to transfection
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reagent only (DharmaFECT 2; Dharmacon). All cell culture experiments were
repeated three to four times using TC prepared from independent batches
of follicles.
Microarray Analysis of Global Gene Expression in TCs Treated with BMP6. For
the microarray study TCs were treated for 4 d with BMP6 (10 ng/mL) under
both basal and LH-stimulated conditions (±160 pg LH/mL). These dose levels
of BMP6 and LH were chosen because they elicited optimal responses in our
previous studies (13, 14). The experiment was replicated four times with TCs
from different batches of ovaries. Total RNA was isolated using the Ribopure
RNA isolation kit (Ambion) according to the manufacturer’s instructions.
RNA yield and quality were evaluated by spectrophotometry at 260/280 nm
and agarose gel electrophoresis before submitting 5 μg of each RNA sample
(n = 16 constituting four biological replicates × four treatment conditions) to
an accredited Affymetrix service provider (Almac Diagnostics Ltd) for
microarray analysis using the bovine genome array GeneChip (Affymetrix).
There are 24,128 probe sets on the array, representing more than 23,000
bovine transcripts and ∼19,000 UniGene clusters. Raw hybridization data
were stored as .cel ﬁles and loaded into Genespring GX (v12.1; Agilent) for
probe summarization (robust multiarray averaging algorithm), ﬁltering, and
statistical analysis using the GeneSpring “biological signiﬁcance” workﬂow
utility for a gene-level experiment. Listed entities passing the expression
level ﬁlter (hybridization signal >20th percentile in at least one sample in
one treatment group) were ﬁltered on statistical signiﬁcance (pairwise
treatment comparisons reaching corrected P < 0.01 using the Benjamini-
Hochberg false discovery rate correction for multiple comparisons) and then
on fold difference (>twofold between treatments) to ensure robust identi-
ﬁcation of up- or down-regulated transcripts. The resultant list of >twofold
up- or down-regulated genes (corrected P < 0.01; unpaired t test with
Benjamini-Hochberg correction) was subjected to GO analysis and sub-
sequently exported to the IPA program (Ingenuity) for gene network anal-
ysis. The raw microarray dataset from this experiment has been submitted to
the Gene Expression Omnibus database (accession no. GSE44704).
RT-qPCR Validation of Microarray Findings. RT-qPCR was used to analyze the
relative abundance of selected transcripts shown to be up- or down-regulated
by BMP6 in the microarray analysis. cDNA samples were prepared from the
same set of total RNA samples used for microarray analysis and used at a 1/50
dilution for qPCR ampliﬁcation as described below.
Effect of BMP6 on Secretion of INSL3 Protein. To verify that the profound
effect of BMP6 treatment on INSL3 mRNA abundance was accompanied by
a corresponding change in the secretion of INSL3 protein by the cells, we
assayed media samples using an immunoassay for bovine INSL3 recently
developed in one of our laboratories (27).
Do Other BMPs Suppress Expression of INSL3 and RXFP2? To ascertain whether
BMPs other than BMP6 also affect TC expression of INSL3 and its receptor we
directly compared the effects of BMP2, -4, -6, and -7 (each at 10 ng/mL, 4-d
treatment) on the secretion of INSL3 protein and A4 by the cells and on the
relativeexpressionofa rangeof transcripts, including INSL3,RXFP2, andCYP17A1.
Time Course of BMP6 Action on Expression of INSL3, RXFP2, and Other
Transcripts. Because a routine 4-d treatment protocol was used in the
above experiments, it was of interest to establish the time course of the TC
response to BMP6. To achieve this we designed a “reverse” time course
experiment in which cultures were terminated and cells were lysed at a ﬁxed
time on day 6 of culture, having been exposed to BMP6 (10 ng/mL) for the
preceding 4-, 24-, 48-, or 96-h period.
Does Knockdown of Endogenous INSL3 or RXFP2 Affect CYP17A1 Expression
and Androgen Secretion? To investigate the effect of knockdown of en-
dogenous INSL3 and RXFP2, TCs were exposed to siRNA duplexes (50 nM ﬁnal
concentration), nonsilencing control duplex (NSC3; Dharmacon; 50 nM), or
transfection reagent only (DharmaFECT 2; 0.25 μL per well). siRNA duplexes
were prepared for transfection as recommended in the supplier’s protocol
(Dharmacon) and added to cells, together with LH (150 pg/mL), after medium
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changes on days 2 and 4 of culture. Cells were lysed 3 d later for RNA ex-
traction and qPCR analysis; media were retained for steroid and INSL3 assay.
Does Synthetic INSL3 Modulate Androgen Secretion by Bovine TC? TC cultured
in the presence and absence of LH (0, 15, 150, or 1,500 pg/mL) were treated
for 4 d with synthetic human INSL3 at ﬁve dose levels, ranging from 0.5 to
5,000 ng/mL. Media were changed and treatments replenished after 2 d.
Viable cell number at the end of culture and concentrations of A4 and
progesterone in conditioned media were determined.
Does Pharmacological Inhibition of Androgen Synthesis Affect Expression of
INSL3 or RXFP2? TC were cultured for 4 d under under LH-stimulated con-
ditions in the presence and absence of abiraterone (100 nM), a potent
CYP17A1 inhibitor. The effects on viable cell number and secretion of A4 and
progesterone were determined.
What Other Intraovarian Factors Affect TC Expression of INSL3? TCs were
cultured for 4 d under basal and LH-stimulated conditions in the presence and
absence of EGF, TGF-α, and TNF-α each at 10 ng/mL We also examined
whether cotreatment of cells with inhibin-A (50 ng/mL) could antagonize
the suppressive effects of BMP4, -6, and -7 (10 ng/mL) on expression of INSL3
mRNA and INSL3 protein secretion.
Real-Time PCR. cDNA was synthesized from 1 μg of total RNA using the
Applied Biosystems high-capacity cDNA reverse transcription kit used
according to the manufacturer’s instructions (Applied Biosystems; Life
Technologies). Primers (Table S4) were designed using Primer Express soft-
ware (Applied Biosystems) or Primer-Blast (www.ncbi.nlm.nih.gov/tools/
primer-blast/). PCR assays were carried out in a volume of 14 μL, comprising
5 μL cDNA (1/50 dilution), 1 μL each forward and reverse primers (ﬁnal
concentration 360 nM), and 7 μL SYBR Green 2× Master Mix (QuantiTect;
Qiagen). Samples were processed on an Applied Biosystems StepOne Plus
real-time PCR instrument (Life Technologies) with the following thermal
cycling conditions: 15 min at 95 °C (one cycle), followed by 15 s at 95 °C and
1 min at 60 °C (40 cycles). Melt curve analysis conﬁrmed ampliﬁcation of
a single product of the predicted melting temperature and absence of
nonspeciﬁc products.
The ΔΔCt method (51) was used for comparison of relative transcript
abundance. Transcript Ct values in a given sample were ﬁrst normalized to
β-actin Ct value (which was uniform across all experimental groups: ANOVA
P > 0.1). Resultant ΔCt values for individual replicates within each treatment
group were then normalized to the mean ΔCt value of vehicle-treated
controls. ΔΔCt values were ﬁnally converted to fold differences using this
formula: fold difference = 2(-ΔΔCt).
Hormone Assays. A4 was determined by an in-house ELISA as fully described in
SI Materials and Methods. The assay detection limit was 30 pg/mL, and mean
intra- and interassay coefﬁcients of variation (CVs) were 7% and 10%, re-
spectively. Progesterone was determined by ELISA (52), with a detection limit
of 0.1 ng/mL and mean intra- and interassay CVs of 6% and 9%, respectively.
Bovine INSL3 was measured using a recently established time-resolved ﬂuo-
rescent immunoassay (27). This homologous assay had a detection limit of
20 pg/mL and had mean intra- and inter-CVs of <2% and <10%, respectively.
Statistical Analysis of Immunoassay and RT-qPCR Data. Hormone secretion
data were analyzed using one- or two-way ANOVA and are presented as
means ± SEM on the basis of four independent culture experiments.
Where indicated, Fischer’s protected least signiﬁcant difference (PLSD) test
was used for post hoc pairwise comparisons. To reduce heterogeneity of
variance, hormone data were log-transformed before statistical analysis.
RT-qPCR data (from at least four independent TC batches) were analyzed
(ANOVA and post hoc Fisher’s PLSD test) as ΔCt values before conversion
to fold difference values for graphical presentation.
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